128 related articles for article (PubMed ID: 1376619)
1. Single agent activity of carboplatin in patients with previously untreated non-seminomatous germ cell tumours.
O'Reilly SM; Rustin GJ; Smith DB; Newlands ES
Ann Oncol; 1992 Feb; 3(2):163-4. PubMed ID: 1376619
[TBL] [Abstract][Full Text] [Related]
2. Significance of the 'maturation' of metastases from germ cell tumours after intensive chemotherapy.
McCartney AC; Paradinas FJ; Newlands ES
Histopathology; 1984 May; 8(3):457-67. PubMed ID: 6203825
[TBL] [Abstract][Full Text] [Related]
3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours.
Lancet; 1985 Jan; 1(8419):8-11. PubMed ID: 2578205
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of pregnancy-specific beta 1-glycoprotein in patients with non-seminomatous testicular germ cell tumors.
de Bruijn HW; Suurmeijer AJ; Sleijfer DT; Koops HS; Ockhuizen T; Willemse PH; Marrink J
Eur J Cancer Clin Oncol; 1982 Oct; 18(10):911-6. PubMed ID: 6186495
[TBL] [Abstract][Full Text] [Related]
6. The UK Children's Cancer Study Group: testicular malignant germ cell tumours 1979-1988.
Huddart SN; Mann JR; Gornall P; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendsus KR
J Pediatr Surg; 1990 Apr; 25(4):406-10. PubMed ID: 1691781
[TBL] [Abstract][Full Text] [Related]
7. Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).
Peckham MJ; Horwich A; Hendry WF
Br J Cancer; 1985 Jul; 52(1):7-13. PubMed ID: 3893507
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin.
Fottner C; Sattarova S; Hoffmann K; Spöttl G; Weber MM
Eur J Endocrinol; 2008 Sep; 159(3):317-27. PubMed ID: 18524796
[TBL] [Abstract][Full Text] [Related]
9. Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976-1980.
Nørgaard-Pedersen B; Schultz HP; Arends J; Brincker H; Krag Jacobsen G; Lindeløv B; Rørth M; Svennekjaer IL
Acta Radiol Oncol; 1984; 23(4):287-94. PubMed ID: 6208749
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in metastatic non-seminomatous germ cell tumours: the Medical Research Council studies.
Mead GM; Stenning SP
Eur Urol; 1993; 23(1):196-200; discussion 201. PubMed ID: 7682951
[TBL] [Abstract][Full Text] [Related]
11. Residual retroperitoneal tumour tissue in patients treated for metastatic non-seminomatous testicular germ cell tumours: an immunohistochemical investigation.
Jacobsen GK; Olsen J
Tumour Biol; 1985; 6(1):25-35. PubMed ID: 2410971
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
[TBL] [Abstract][Full Text] [Related]
13. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.
Logothetis CJ; Swanson DA; Dexeus F; Chong C; Ogden S; Ayala AG; von Eschenbach AC; Johnson DE; Samuels ML
J Clin Oncol; 1987 Jun; 5(6):906-11. PubMed ID: 2438389
[TBL] [Abstract][Full Text] [Related]
14. Current optimum management of anaplastic germ cell tumours of the testis and other sites.
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Crawford SM; Holden L
Br J Urol; 1986 Jun; 58(3):307-14. PubMed ID: 2424538
[TBL] [Abstract][Full Text] [Related]
15. The value of alpha-fetoprotein and beta-human chorionic gonadotrophin in the management of testicular tumours.
Narayana AS; Loening S; Culp DA
Br J Urol; 1978 Dec; 50(7):605-8. PubMed ID: 88986
[TBL] [Abstract][Full Text] [Related]
16. Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours?
McAleer JJ; Nicholls J; Horwich A
Eur J Cancer; 1992; 28A(4-5):825-8. PubMed ID: 1381929
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with poor prognosis anaplastic germ cell tumours (AGCT) of the testis and other sites.
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Crawford SM; Holden L
Int J Androl; 1987 Feb; 10(1):301-9. PubMed ID: 2438223
[TBL] [Abstract][Full Text] [Related]
19. cis-Diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary report.
Peckham MJ; Horwich A; Brada M; Drury A; Hendry WF
Cancer Treat Rev; 1985 Sep; 12 Suppl A():101-10. PubMed ID: 3002622
[TBL] [Abstract][Full Text] [Related]
20. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
